abt-165
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 27, 2013 (NCT01946074)
Timeline
Indications
Studied for
Mechanism of action
- Delta-like protein 4Immunity, passive
DLL4 immunity, passive
- Vascular endothelial growth factor AImmunity, passive
VEGFA immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- abt-165
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03368859 | Phase 2 | Feb 19, 2018 | AbbVie |
| NCT01946074 | Phase 1 | Aug 27, 2013 | AbbVie |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 2 | 2 | 2 | 2013 |
1 organizations
Page 1 / 1